Padsevonil

Anticonvulsant drug

Padsevonil
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Padsevonil is an investigational anticonvulsant drug developed for the treatment of epilepsy. It is designed to target both synaptic vesicle protein 2A (SV2A) and the GABAergic system, offering a novel mechanism of action compared to existing antiepileptic drugs.

Mechanism of Action

Padsevonil acts by binding to the SV2A protein, which is involved in the regulation of neurotransmitter release in the brain. This binding is thought to modulate synaptic transmission and reduce the frequency of seizures. Additionally, Padsevonil enhances the activity of the GABAergic system, which is the primary inhibitory neurotransmitter system in the central nervous system. By enhancing GABAergic inhibition, Padsevonil helps to stabilize neuronal activity and prevent the excessive neuronal firing that characterizes epileptic seizures.

Pharmacokinetics

The pharmacokinetic profile of Padsevonil includes rapid absorption and a moderate half-life, allowing for convenient dosing schedules. It is metabolized primarily in the liver and excreted through the kidneys. The drug's pharmacokinetics are designed to provide consistent therapeutic levels with minimal fluctuations, reducing the risk of breakthrough seizures.

Clinical Trials

Padsevonil has undergone several phases of clinical trials to evaluate its efficacy and safety in patients with drug-resistant epilepsy. These trials have demonstrated that Padsevonil can significantly reduce seizure frequency in patients who have not responded to other treatments. The drug is generally well-tolerated, with the most common side effects being dizziness, somnolence, and headache.

Development and Future Directions

Padsevonil is being developed by UCB Pharma, a company with a strong focus on neurological disorders. The drug represents a promising addition to the arsenal of treatments available for epilepsy, particularly for patients with drug-resistant forms of the condition. Ongoing research is focused on optimizing dosing regimens and exploring the potential of Padsevonil in other neurological disorders.

Related pages

• Epilepsy
• Anticonvulsant
• Synaptic vesicle protein 2A
• GABA